Search

Your search keyword '"Hematyar, Javad"' showing total 5 results
Start Over Author "Hematyar, Javad"
5 results on '"Hematyar, Javad"'

1. The effect of spirulina sauce on glycemic index, lipid profile, and oxidative stress in type 2 diabetic patients: A randomized double‐blind clinical trial

Author

Rezaiyan, Mojtaba, primary, Sasani, Najmeh, additional, Kazemi, Asma, additional, Mohsenpour, Mohammad Ali, additional, Babajafari, Siavash, additional, Mazloomi, Seyed Mohammad, additional, Clark, Cain C. T., additional, Hematyar, Javad, additional, Ghaem Far, Zohreh, additional, Azadian, Mohsen, additional, and Zareifard, Alireza, additional

Published
2023
Full Text
View/download PDF

2. Evaluating the effect of cow's milk fortified with albumin powder on malnutrition and anthropometric indices in primary-school children with mild-to-moderate underweight: A randomized double-blinded clinical trial.

Author

Davarpanah, Hajar, Ziaee, Roxaneh Sadat, Esmaeilinezhad, Zahra, Etemadfar, Peyman, Hematyar, Javad, Babajafari, Siavash, and Barati-Boldaji, Reza

Subjects
MALNUTRITION treatment, BODY weight, ENRICHED foods, ANTHROPOMETRY, MILK, SERUM albumin, LEANNESS, DIETARY supplements, TREATMENT effectiveness, RANDOMIZED controlled trials, COMPARATIVE studies, BLIND experiment, DESCRIPTIVE statistics, RESEARCH funding, SCHOOL children, STATISTICAL sampling, BODY mass index, NUTRITION disorders in children
Abstract

Background: A proper diet plan is one of the necessary conditions for maintaining the children's health. The aim of this study was to evaluate the effect of consumption of pasteurized cow's milk fortified with albumin protein in primary-school children, in Yasuj, Iran. Materials and Methods: In this double-blind randomized clinical trial with 12 weeks of duration, 60 children aged 7-13 years, mild to moderate underweight (-1≥ weight-for-age z-score ≥-3), were randomly assigned to control and albumin groups. The albumin group and the control group received 200 cc of milk with 10 g of albumin powder and 200 cc of milk with 10 g of cornstarch powder, respectively. At the beginning and end of the study, food intake and anthropometric indices were measured. Results: After 12 weeks of intervention, none of the anthropometric indices (weight, weight-for-age z-score, body mass index (BMI), BMI-for-age z-score, and waist circumference) showed significant changes as compared to baseline in the control group, but weight-for-age z-score and BMI-for-age z-score showed significant increase as compared to baseline in the albumin group (before: -2.25 ± 0.40, after: -1.98 ± 0.35, P = 0.001 and before: -3.48 ± 0.86, after: -3.06 ± 0.71, P = 0.009, respectively). The comparison of the mean changes between the two groups showed significant difference regarding weight-for-age z-score (control group: -1.70 ± 0.31 in comparison with albumin group: -1.98 ± 0.35, P = 0.002), BMI (control group: 12.08 ± 1.96 in comparison with albumin group: 12.13 ± 1.49, P = 0.03), and BMI-for-age z-score (control group: -3.11 ± 0.91 in comparison with albumin group: -3.06 ± 0.71, P = 0.02). Conclusion: The consumption of albumin powder with milk can improve weight-for-age z-score and BMI-for-age z-score indices in children with mild-to-moderate underweight. Larger controlled interventional studies with longer duration are recommended. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Effect of Sitagliptin Versus Glibenclamide on Glycemic Markers, Lipid Profile Inflammatory and Oxidative Stress Factors in Type 2 Diabetes Patients: a Double-Blinded Randomized Controlled Trial

Author

HEMATYAR, Javad, RASHIDI, Homeira, ZAKERKISH, Mehrnoosh, PAYAMI, Seyed Peyman, and GHADERIAN, Seyed Bahman

Subjects
Original Paper
Abstract

Objectives:Diabetes mellitus is leading to chronic complications, including cardiovascular diseases. The aim of this study was to compare the effect of Sitagliptin and Glibenclamide on glycemic markers, lipid profile inflammatory, and oxidative stress factors in type 2 diabetes patients. Methods: This double-blinded randomized controlled trial was performed on patients with type 2 diabetes mellitus (n=54). The treatment group (27 patients) received 100 mg of Sitagliptin once daily + 500 mg Metformin twice daily, orally, for 12 weeks, and the control group (27 patients) was given 5 mg of Glibenclamide once daily + 500 mg Metformin twice daily, also orally, for 12 weeks. Serum levels of tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipid profile [cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG)], fasting blood sugar (FBS) and hemoglobin A1C (HbA1c), body weight, and body mass index (BMI) were measured before and after the study. Results:In both groups, the FBS level was significantly reduced from baseline (P=0.03 in the Sitagliptin group and P=0.02 in the Glibenclamide one). The percent of HbA1c was also significantly reduced from baseline in both the Sitagliptin group (P=0.01) and the Glibenclamide one (P=0.008). However, comparing the groups, these changes were not different. In the Sitagliptin group, IL-6 was significantly reduced from baseline (P=0.01) as well as in comparison with the Glibenclamide group (P=0.001). The TG level was significantly lower than the baseline in the Sitagliptin group (P=0.03), so changes between groups were significant (P=0.04). Weight and BMI were significantly increased from baseline in the Glibenclamide group (P=0.02 and P=0.03, respectively), and their changes between the two groups were also significant (P=0.001). Conclusion:These finding support the favorable effects of Sitagliptin on cardiovascular risks beyond its advantages on insulin-glucose hemostasis in patients with type 2 diabetes.

Published
2022

5. Effect of Sitagliptin Versus Glibenclamide on Glycemic Markers, Lipid Profile Inflammatory and Oxidative Stress Factors in Type 2 Diabetes Patients: a Double-Blinded Randomized Controlled Trial.

Author

Hematyar J, Rashidi H, Zakerkish M, Payami SP, and Ghaderian SB

Abstract

Objectives: Diabetes mellitus is leading to chronic complications, including cardiovascular diseases. The aim of this study was to compare the effect of Sitagliptin and Glibenclamide on glycemic markers, lipid profile inflammatory, and oxidative stress factors in type 2 diabetes patients. Methods: This double-blinded randomized controlled trial was performed on patients with type 2 diabetes mellitus (n=54). The treatment group (27 patients) received 100 mg of Sitagliptin once daily + 500 mg Metformin twice daily, orally, for 12 weeks, and the control group (27 patients) was given 5 mg of Glibenclamide once daily + 500 mg Metformin twice daily, also orally, for 12 weeks. Serum levels of tumor necrosis factor alpha (TNF-α), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), lipid profile [cholesterol, low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG)], fasting blood sugar (FBS) and hemoglobin A1C (HbA1c), body weight, and body mass index (BMI) were measured before and after the study. Results: In both groups, the FBS level was significantly reduced from baseline (P=0.03 in the Sitagliptin group and P=0.02 in the Glibenclamide one). The percent of HbA1c was also significantly reduced from baseline in both the Sitagliptin group (P=0.01) and the Glibenclamide one (P=0.008). However, comparing the groups, these changes were not different. In the Sitagliptin group, IL-6 was significantly reduced from baseline (P=0.01) as well as in comparison with the Glibenclamide group (P=0.001). The TG level was significantly lower than the baseline in the Sitagliptin group (P=0.03), so changes between groups were significant (P=0.04). Weight and BMI were significantly increased from baseline in the Glibenclamide group (P=0.02 and P=0.03, respectively), and their changes between the two groups were also significant (P=0.001). Conclusion: These finding support the favorable effects of Sitagliptin on cardiovascular risks beyond its advantages on insulin-glucose hemostasis in patients with type 2 diabetes.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results